Rater evaluations for psychiatric instruments and cultural differences: The positive and negative syndrome scale in China and the United States

Journal of Nervous and Mental Disease

Volumn 200, Issue 9, 2012, Pages 814-820

  Aggarwal, Neil Krishan ^a,b,c   Zhang, Xiang Yang ^d,e   Stefanovics, Elina ^a,f   Chen, Da Chun ^a   Xiu, Mei Hong ^a   Xu, Ke ^a,c   Rosenheck, Robert A ^a,f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e BEIJING HUILONGGUAN HOSPITAL   (China)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

cultural psychiatry; ethnopsychology; PANSS; rating scales; Schizophrenia

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHINA; CULTURAL ANTHROPOLOGY; DISEASE DURATION; EMPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSOCIAL WITHDRAWAL; RACE DIFFERENCE; SCHIZOPHRENIA; STIGMA; UNITED STATES;

ADOLESCENT; ADULT; AGED; CHINA; CROSS-CULTURAL COMPARISON; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; UNITED STATES;

EID: 84865860309     PISSN: 00223018     EISSN: 1539736X     Source Type: Journal    
DOI: 10.1097/NMD.0b013e318266bcaa     Document Type: Article

References (38)

1. Abu-Lughod L, Lutz CA (1990) Introduction: Emotion, discourse, and the politics of everyday life. In Lutz CA, Abu-Lughod L (Eds), Language and the politics of emotion (1st ed, pp 1-23). Cambridge: Cambridge University Press.
2. Aggarwal NK (2007) Exploring identity, culture, and suffering with a Kashmiri Sikh refugee. Soc Sci Med. 65:1654-1665.
3. Aggarwal NK, Tao H, Xu K, Stefanovics E, Zhening L, Rosenheck RA (2011) Comparing the PANSS in Chinese and American inpatients: Cross-cultural psychiatric analyses of instrument translation and implementation. Schizophr Res. 132:146-52.
4. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN (1997) Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 7:125-137.
5. Cong Y (2004) Doctor-family-patient relationship: The Chinese paradigm of informed consent. J Med Philos. 29:149-178.
6. Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, Starkstein S, Oliva D, Cousins L, Tohen M, Taylor CC, Wang J, Tran PV (2001) Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: Results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol. 21:375-381.
7. Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D; Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia (2001) Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull. 27:227-234.
8. Devereux G (2000) Normal and abnormal. In Littlewood R, Dein S (Eds), Cultural psychiatry and medical anthropology: An introduction and reader (1st ed, pp 213-289). London: The Athlone Press.
9. Ertan T, Eker E (2000) Reliability, validity, and factor structure of the geriatric depression scale in Turkish elderly: Are there different factor structures for different cultures? Int Psychogeriatr. 12:163-172.
10. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH (2008) A multiple-center, randomized, doubleblind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 165:1432-1441.
11. Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y (2009) The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs. 23:615-625.
12. Igarashi Y, Hayashi N, Yamashina M, Otsuka N, Kuroki N, Anzai N, Kazamatsuri H (1998) Interrater reliability of the Japanese version of the Positive and Negative Syndrome Scale and the appraisal of its training effect. Psychiatry Clin Neurosci. 52:467-470.
13. Kane JM, Khanna S, Rajadhyaksha S (2006) Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 21:21-28.
14. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 6:325-337.
15. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 13:261-276.
16. Kirmayer LJ (2007) Cultural psychiatry in historical perspective. In Bhugra D, Bhui K (Eds), Textbook of cultural psychiatry (1st ed, pp 3-19). Cambridge: Cambridge University Press.
17. Kleinman A (1988) Rethinking psychiatry: From cultural category to personal experience. New York: The Free Press.
18. Kleinman A (1996) How is culture important for DSM-IV? In Mezzich JE, Kleinman A, Fabrega H Jr, Parron DL (Eds), Culture and psychiatric diagnosis: A DSM-IV perspective (1st ed, pp 15-29). Washington, DC: American Psychiatric Press.
19. Lancnon C, Reine G, Llorca PM, Auquier P (1999) Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS). Acta Psychiatr Scand. 100:237-243.
20. Lasser RA, Bossie CA, Gharabawi GM, Turner M (2004) Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry. 19:219-225.
21. Lee CT, Conde BJ, Mazlan M, Visanuyothin T, Wang A, Wong MM, Walker DJ, Roychowdhury SM, Wang H, Tran PV (2002) Switching to olanzapine from previous antipsychotics: A regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry. 63:569-576.
22. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R (2005) Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 187: 366-371.
23. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353:1209-1223.
24. Lim CS, Subramaniam M, Poon LY, Chong SA, Verma S (2011) Cross-ethnic differences in severity of symptomatology of individuals with first-episode schizophrenia spectrum disorder. Early Interv Psychiatry. 5:242-248.
25. Mechri A, Bourdel MC, Slama H, Gourion D, Gaha L, Krebs MO (2009) Neurological soft signs in patients with schizophrenia and their unaffected siblings: Frequency and correlates in two ethnic and socioeconomic distinct populations. Eur Arch Psychiatry Clin Neurosci. 259:218-226.
26. Nilchaikovit T, Uneanong S, Kessawai D, Thomyangkoon P (2000) The Thai version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia: Criterion validity and interrater reliability. J Med Assoc Thai. 83:646-651.
27. Olie JP, Spina E, Murray S, Yang R (2002) Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: Results of a 12-week, double-blind study. Int Clin Psychopharmacol. 21:143-151.
28. Phillips MR, XiongW,Wang RW, Gao YH,Wang XQ, Zhang NP (1991) Reliability and validity of the Chinese versions of the Scales for Assessment of Positive and Negative Symptoms. Acta Psychiatr Scand. 84:364-370.
29. Roe D, Ravidson L (2001) Self and narrative in schizophrenia: Time to author a new story. Med Humanit. 31:89-94.
30. Rosenheck RA, Sernyak MJ (2009) Developing a policy for second-generation antipsychotic drugs. Health Aff (Millwood). 28:w782-w793.
31. Ryckmans V, Kahn JP, Modell S, Werner C, McQuade RD, Kerselaers W, Lissens J, Sanchez R (2009) Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: A randomized, multicentre, open-label study. Pharmacopsychiatry. 42: 114-121.
32. Sass LA (2001) Self and world in schizophrenia: Three classic approaches. Philos Psychiatr Psychol. 8:251-270.
33. Tang YL, Gillespie CF, Epstein MP, Mao PX, Jiang F, Chen Q, Cai ZJ, Mitchell PB (2007) Gender differences in 542 Chinese inpatients with schizophrenia. Schizophr Res. 97:88-96.
34. Tsai DF (2001) How should doctors approach patients? A Confucian reflection on personhood. J Med Ethics. 27:44-50.
35. Van Os J, Bossie CA, Lasser RA (2004) Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol. 19:229-232.
36. von Knorring L, LindstroTm E (1992) The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability. Acta Psychiatr Scand. 86:463-468.
37. Yang LH, Phillips MR, Lo G, Chou Y, Zhang X, Hopper K (2010) 'Excessive thinking' as explanatory model for schizophrenia: Impacts on stigma and 'moral' status in Mainland China. Schizophr Bull. 36:836-845.
38. Zhang XY, Chen da C, Qi LY,Wang F, Xiu MH, Chen S,Wu GY, Kosten TA, Kosten TR (2009) Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology (Berl). 205:647-654.